634 related articles for article (PubMed ID: 8363355)
21. Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
Macdonald IR; Reid GA; Pottie IR; Martin E; Darvesh S
J Nucl Med; 2016 Feb; 57(2):297-302. PubMed ID: 26541777
[TBL] [Abstract][Full Text] [Related]
22. Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
Kar S; Poirier J; Guevara J; Dea D; Hawkes C; Robitaille Y; Quirion R
Neurobiol Aging; 2006 Feb; 27(2):199-210. PubMed ID: 16399207
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type.
Atack JR; May C; Kaye JA; Kay AD; Rapoport SI
Ann Neurol; 1988 Feb; 23(2):161-7. PubMed ID: 3377438
[TBL] [Abstract][Full Text] [Related]
24. APOE, vascular pathology, and the AD brain.
Yip AG; McKee AC; Green RC; Wells J; Young H; Cupples LA; Farrer LA
Neurology; 2005 Jul; 65(2):259-65. PubMed ID: 16043796
[TBL] [Abstract][Full Text] [Related]
25. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
Mesulam M; Guillozet A; Shaw P; Quinn B
Neurobiol Dis; 2002 Feb; 9(1):88-93. PubMed ID: 11848688
[TBL] [Abstract][Full Text] [Related]
26. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
[TBL] [Abstract][Full Text] [Related]
27. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes.
Pugliese M; Gangitano C; Ceccariglia S; Carrasco JL; Del Fà A; Rodríguez MJ; Michetti F; Mascort J; Mahy N
Brain Res; 2007 Mar; 1139():85-94. PubMed ID: 17292335
[TBL] [Abstract][Full Text] [Related]
28. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
29. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology.
Attems J; Lintner F; Jellinger KA
Acta Neuropathol; 2004 Apr; 107(4):283-91. PubMed ID: 14986026
[TBL] [Abstract][Full Text] [Related]
30. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.
Wright CI; Guela C; Mesulam MM
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):683-6. PubMed ID: 8421706
[TBL] [Abstract][Full Text] [Related]
31. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Arendt T; Brückner MK; Lange M; Bigl V
Neurochem Int; 1992 Oct; 21(3):381-96. PubMed ID: 1303164
[TBL] [Abstract][Full Text] [Related]
32. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains.
Pearson AG; Byrne UT; MacGibbon GA; Faull RL; Dragunow M
Neurosci Lett; 2006 May; 398(3):246-50. PubMed ID: 16481106
[TBL] [Abstract][Full Text] [Related]
33. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F
Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322
[TBL] [Abstract][Full Text] [Related]
34. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas.
Soneira CF; Scott TM
Clin Anat; 1996; 9(2):118-27. PubMed ID: 8720786
[TBL] [Abstract][Full Text] [Related]
35. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease.
Hatanpää K; Brady DR; Stoll J; Rapoport SI; Chandrasekaran K
Ann Neurol; 1996 Sep; 40(3):411-20. PubMed ID: 8797530
[TBL] [Abstract][Full Text] [Related]
36. Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages.
Ghebremedhin E; Thal DR; Schultz C; Braak H; Deller T
Acta Neuropathol; 2007 Oct; 114(4):359-63. PubMed ID: 17701416
[TBL] [Abstract][Full Text] [Related]
37. Regression stage senile plaques in the natural course of Alzheimer's disease.
Oide T; Kinoshita T; Arima K
Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888
[TBL] [Abstract][Full Text] [Related]
38. Multiple sclerosis and Alzheimer's disease.
Dal Bianco A; Bradl M; Frischer J; Kutzelnigg A; Jellinger K; Lassmann H
Ann Neurol; 2008 Feb; 63(2):174-83. PubMed ID: 17924575
[TBL] [Abstract][Full Text] [Related]
39. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
40. Alzheimer's disease severely affects areas of the claustrum connected with the entorhinal cortex.
Morys J; Bobinski M; Wegiel J; Wisniewski HM; Narkiewicz O
J Hirnforsch; 1996; 37(2):173-80. PubMed ID: 8776503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
